Enveric Biosciences reports positive preclinical study results for EB-003
ENVB•Enveric Biosciences reported positive results from IND-enabling laboratory studies of EB-003, with screening across more than 70 assays indicating favorable intestinal absorption potential, metabolic stability and low potential for drug interactions.
1. Study results
Enveric Biosciences reported positive results from IND-enabling laboratory studies of EB-003, its lead non-hallucinogenic neuroplastogenic drug candidate. Screening across more than 70 assays indicated favorable intestinal absorption potential, metabolic stability and low potential for drug interactions. The results support continued development toward a planned first-in-human clinical trial.
